At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.
At the 2023 ESMO Congress,...